Diffuse Large B-Cell Lymphoma Activated B-Cell Type
3 clinical trials · Condition
◉ Watch Diffuse Large B-Cell Lymphoma Activated B-Cell Type
| Record | Firm | Date |
|---|---|---|
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275) | National Cancer Institute (NCI) | 2021-05-20 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672) | National Cancer Institute (NCI) | 2018-12-21 |
Track Diffuse Large B-Cell Lymphoma Activated B-Cell Type automatically
Every clearance here is in the API, with alerts when new ones post.